FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia

Blood

Volumn 112, Issue 1, 2008, Pages 179-187

  Li, Fu Jun ^a   Ding, Shouluan ^b   Pan, Jicun ^a   Shakhmatov, Mikhail A ^a   Kashentseva, Elena ^a   Wu, Jiongru ^a   Li, Yufeng ^b   Soong, Seng Jaw ^b   Chiorazzi, Nicholas ^c,d   Davis, Randall S ^a,b,e,f,g  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD38 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY VARIABLE; MONOCLONAL ANTIBODY; PROTEIN FC RECEPTOR LIKE 1; PROTEIN FC RECEPTOR LIKE 2; PROTEIN FC RECEPTOR LIKE 3; PROTEIN FC RECEPTOR LIKE 4; PROTEIN FC RECEPTOR LIKE 5; PROTEIN KINASE ZAP 70; UNCLASSIFIED DRUG; CD38 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; FCRL1 PROTEIN, HUMAN; FCRL2 PROTEIN, HUMAN; FCRL3 PROTEIN, HUMAN; FCRL5 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; B CELL LEUKEMIA; CASE CONTROL STUDY; COHORT ANALYSIS; GENETICS; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MUTATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; B-LYMPHOCYTES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENE EXPRESSION; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MUTATION; PROGNOSIS; RECEPTORS, CELL SURFACE; RECEPTORS, IMMUNOLOGIC; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 47249146983     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-131359     Document Type: Article

References (62)

1. Cheson BD. Bennett JM. Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
2. Wierda WG, O'Brien S, Wang X et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109:4679-4685.
3. Rosenwald A. Alizadeh AA. Widhopf G. et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639-1647.
4. Klein U, Tu Y, Stolovitzky GA. et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625-1638.
5. Damle RN, Ghiotto F, Valetto A. et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigenexperienced B lymphocytes. Blood. 2002;99:4087-4093.
6. Schroeder HW Jr. Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today. 1994;15:288-294.
7. Fais F. Ghiotto F. Hashimoto S. et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515-1525.
8. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005:352:804-815.
9. Damle RN. Wasil T, Fais F, et al. lg V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999:94:1840-1847.
10. Hamblin TJ, Davis Z. Gardiner A. Oscier DG. Stevenson FK. Unmutated lg V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999:94:1848-1854.
11. Ibrahim S, Keating M. Do KA. et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98:181-186.
12. Hamblin TJ, Orchard JA, Ibbotson RE. et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023-1029.
13. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944-4951.
14. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulinvariable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003:348:1764-1775.
15. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004:363:105-111.
16. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004:351:893-901.
17. Del Principe Ml, Del Poeta G, Buccisano F, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood. 2006:108:853-861.
18. Titus K. Zigs and zags on the ZAP-70 highway. CAP Today. 2004;18:1.
19. Gibbs G, Bromidge T, Howe D, Hopkins J, Johnson S. Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory. Clin Lab Haematol. 2005:27:258-266.
20. Letestu R, Rawstron A, Ghia P, et al. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: a multicentric international harmonization process. Cytometry B Clin Cytom. 2006:70:309-314.
21. Wilhelm C, Neubauer A, Brendel C. Discordant results of flow cytometric ZAP-70 expression status in B-CLL samples if different gating strategies are applied. Cytometry B Clin Cytom. 2006;70:242-250.
22. Marti G, Orfao A, Goolsby C. ZAP-70 in CLL: towards standardization of a biomarker for patient management: history of clinical cytometry special issue. Cytometry B Clin Cytom. 2006:70:197-200.
23. Munoz L, Lasa A, Carricondo MT, et al. Comparative analysis of ZAP-70 expression and lg VH mutational status in B-cell chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2007;72:96-102.
24. Chen YH, Peterson LC, Dittmann D, et al. Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to lgVH mutational status in chronic lymphocytic leukemia. Am J Clin Pathol. 2007:127:182-191.
25. Marti G, Orfao A, Goolsby CL. ZAP70 editorial: a follow-up to the special issue. Cytometry B Clin Cytom. 2007:72:94-95.
26. Hatzivassiliou G, Miller I, TakizawaJ, et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity. 2001;14:277-289.
27. Davis RS, Wang YH, Kubagawa H, Cooper MD. Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci U S A. 2001:98:9772-9777.
28. Miller I, Hatzivassiliou G, Cattoretti G, Mendelsohn C, Dalla-Favera R. IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells. Blood. 2002:99:2662-2669.
29. Leu CM, Davis RS, Gartland LA, Fine WD, Cooper MD. FcRH1: an activation coreceptor on human B cells. Blood. 2005:105:1121-1126.
30. Ehrhardt GR, Hsu JT, Gartland L, et al. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J Exp Med. 2005;202:783-791.
31. Poison AG, Zheng B, Elkins K, et al. Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol. 2006:18:1363-1373.
32. Davis RS. Fc receptor-like molecules. Annu Rev Immunol. 2007:25:525-560.
33. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
34. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003:3:185-197.
35. Huttmann A, Klein-Hitpass L, Thomale J, et al. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. Leukemia. 2006;20:1774-1782.
36. Du X, Nagata S, Ise T, Stetler-Stevenson M, Pastan I. FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia and B-cell non-Hodgkin's lymphoma as a target of immunotoxins. Blood. 2008; 111:338-343.
37. Ehrhardt GR, Davis RS, Hsu JT, et al. The inhibitory potential of Fc receptor homolog 4 on memory B cells. Proc Natl Acad Sci U S A. 2003:100:13489-13494.
38. Kearney JF, Radbruch A, Liesegang B, Rajewsky K. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol. 1979:123:1548-1550.
39. Rassenti LZ, Kipps TJ. Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2006;70:209-213.
40. Garff-Tavernier M, Ticchioni M, Brissard M, et al. National standardization of ZAP-70 determination by flow cytometry: the French experience. Cytometry B Clin Cytom. 2007:72:103-108.
41. Campbell MJ, Zelenetz AD, Levy S, Levy R. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol. 1992;29:193-203.
42. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982:143:29-36.
43. Zhang H, Singer B. Recursive Partitioning in the Health Sciences. Berlin: Springer; 1999.
44. Harrell FEJr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982:247:2543-2546.
45. Fox W. Social Statistics, 3rd ed. Bellevue, WA: Microcase Corporation; 1998.
46. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004:103:4389-4395.
47. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008:111:1524-1533.
48. Tobin G, Soderberg O, Thunberg U, Rosenquist R. V(H)3-21 gene usage in chronic lymphocytic leukemia: characterization of a new subgroup with distinct molecular features and poor survival. Leuk Lymphoma. 2004;45:221-228.
49. Krober A, SeilerT, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002:100:1410-1416.
50. Kern W, Dicker FSS, Haferlach C, Haferlach T. Flow cytometric determination of ZAP-70 expression by SBZAP antibody: impact of type of data analysis on correlation with IgVH mutation status, cytogenetics, and level of ZAP-70 mRNA expression in 351 patients with chronic lymphocytic leukemia (CLL) [abstract]. Blood. 2007;110: abstract no. 4682.
51. Barnhart HX, Haber M, Song J. Overall concordance correlation coefficient for evaluating agreement among multiple observers. Biometrics. 2002:58:1020-1027.
52. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
53. Kochi Y Yamada R, Suzuki A, et al. Afunctional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat Genet. 2005;37:478-485.
54. Ise T, Maeda H, Santora K, et al. Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies. Clin Cancer Res. 2005;11:87-96.
55. Hamblin TJ, Davis ZA, Oscier DG. Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia - long-term follow up of patients with different percentages of mutations. Br J Haematol. 2008:140:320-323.
56. Haga CL, Ehrhardt GR, Boohaker RJ, Davis RS, Cooper MD. Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment. Proc Natl Acad Sci U S A. 2007;104:9770-9775.
57. Xu MJ, Zhao R, Zhao ZJ. Molecular cloning and characterization of SPAP1, an inhibitory receptor. Biochem Biophys Res Commun. 2001;280:768-775.
58. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol. 200321:841-894.
59. Klein U, la-Favera R. New insights into the phenotype and cell derivation of B cell chronic lymphocytic leukemia. CurrTop Microbiol Immunol. 2005:294:31-49.
60. Dono M, Burgio VL, Colombo M, et al. CD5(+) B cells with the features of subepithelial B cells found in human tonsils. Eur J Immunol. 2007;37:2138-2147.
61. Weller S, Braun MC, Tan BK, et al. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a pre-diversified immunoglobulin repertoire. Blood. 2004;104:3647-3654.
62. Won WJ, Foote JB, Odom MR, et al. Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and b1 B cells. J Immunol. 2006; 177:6815-6823.